| abstract |
The vascular endothelial cell growth factor receptor, neuropilin, is a selective binding partner for the anti-angiogenic molecule T2-TrpRS. This binding inhibits VEGF-mediated activity by effectively blocking VEGF binding to neuropilin. It is hypothesized that T2- TrpRS acts as a competitive antagonist of VEGF-neuropilin interaction with consequent disruption of angiogenesis. This discovery is exploited to provide novel methods for the treatment of diseases and conditions impacted by T2- TrpRS or T2- TrpRS derivatives via their interaction with neuropilins. |